Nintedanib (Ofev®) 14 is an indolinone-derived intracellular tyrosine kinase inhibitor drug awarded FDA approval against NSCLC (non-small cell lung cancer) with potential anti-angiogenesis properties and inhibitory activity against PDGFR-α, -β; VEGFR-1, -2, -3; and FGFR-1, -2, -3 (fibroblast growth factor receptor) [52,53,54,55,56,57]. Here, PDGFRA is linked to non-small cell lung carcinoma.